On 28th of April, The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published version 3 of their guidance to sponsors on how to manage clinical trials during the COVID-19 (Coronavirus) pandemic.
Key changes from v2 (27-03-2020): distributor to trial participant IMP shipment, monitoring, remote source data verification and communication with authorities